廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,010.66
    +17.52 (+0.59%)
     
  • 道指

    39,760.08
    +477.75 (+1.22%)
     
  • 標普 500

    5,248.49
    +44.91 (+0.86%)
     
  • 納指

    16,399.52
    +83.82 (+0.51%)
     
  • Vix指數

    13.00
    +0.22 (+1.72%)
     
  • 富時100

    7,953.91
    +21.93 (+0.28%)
     
  • 紐約期油

    82.64
    +1.29 (+1.59%)
     
  • 金價

    2,231.30
    +18.60 (+0.84%)
     
  • 美元

    7.8247
    +0.0016 (+0.02%)
     
  • 人民幣

    0.9233
    +0.0001 (+0.01%)
     
  • 日圓

    0.0515
    +0.0000 (+0.06%)
     
  • 歐元

    8.4614
    -0.0078 (-0.09%)
     
  • Bitcoin

    70,785.02
    +613.26 (+0.87%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq

The FDA approved AbbVie Inc's (NASDAQ: ABBV) Rinvoq (upadacitinib) for moderately to severely active Crohn's disease patients with inadequate response or intolerance to one or more TNF blockers.

This is the seventh FDA approval for Rinvoq across rheumatology, dermatology, and gastroenterology, where it is now indicated in both ulcerative colitis and Crohn's disease.

The FDA noted that Rinvoq is the first oral drug. Though there are several other biologics already on the market to treat moderately to severely active Crohn's, including Johnson & Johnson's (NYSE: JNJ) Stelara, Takeda Pharmaceutical Co Limited's (NYSE: TAK) Entyvio and AbbVie's Skyrizi.

廣告

The approval was based on results from three studies, the U-EXCEED and U-EXCEL initial trial and the U-ENDURE maintenance trial, determining statistical significance in the co-primary endpoints of endoscopic response and clinical remission.

In AbbVie's most recent Q1 report, Skyrizi sales reached $1.36 billion, while Rinvoq had sales of $686 million.

Price Action: ABBV shares are down 0.06% at $143.35 during the premarket session on the last check Friday.

Photo via Wikimedia Commons

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.